Semaglutide, found in Novo Nordisk's Ozempic, may reduce Alzheimer's risk in type 2 diabetes patients, per new research. FDA ...

Semaglutide, the active ingredient found in Ozempic and Wegovy, may reduce the risk of Alzheimer’s disease, a new study published Thursday morning finds.

A new study is adding to evidence that GLP-1 drugs such as Novo Nordisk's semaglutide and Eli Lilly's tirzepatide could also ...

Advocates for diabetes patients who need insulin to survive worry the nation's supply is unreliable. Meanwhile, use of ...

Novo Nordisk’s blockbuster drug Ozempic (NVO) is linked to yet another health benefit. This time it’s lowering the risk of ...

Novo Nordisk (NVO) has asked the FDA to ban cheap copies of its weight loss drugs Wegovy and Ozempic, arguing they pose safety risks, ...

Researchers have linked Novo Nordisk’s semaglutide to a 40% to 70% reduction in the risk of Alzheimer’s disease diagnosis in ...

Semaglutide is a glucagon-like peptide-1 (GLP-1) drug, and is the active agent in Ozempic and its weight-loss cousin, Wegovy.

Lilly will launch its Mounjaro obesity drug in Denmark next week, the U.S. drugmaker said on Thursday, bringing competition ...

The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in ...

The insulin is facing supply shortages as diabetes patients increasingly turn to GLP-1 weight loss drugs such as Ozempic and ...

Rise and shine, everyone, another busy day is on the way. We can tell because the pace of motor vehicles passing by our ...